Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Vaccines (Basel) ; 11(5)2023 May 11.
Article in English | MEDLINE | ID: covidwho-20235810

ABSTRACT

Populations affected by humanitarian crises and emerging infectious disease outbreaks may have unique concerns and experiences that influence their perceptions toward vaccines. In March 2021, we conducted a survey to examine the perceptions toward COVID-19 vaccines and identify the factors associated with vaccine intention among 631 community members (CMs) and 438 healthcare workers (HCWs) affected by the 2018-2020 Ebola Virus Disease outbreak in North Kivu, Democratic Republic of the Congo. A multivariable logistic regression was used to identify correlates of vaccine intention. Most HCWs (81.7%) and 53.6% of CMs felt at risk of contracting COVID-19; however, vaccine intention was low (27.6% CMs; 39.7% HCWs). In both groups, the perceived risk of contracting COVID-19, general vaccine confidence, and male sex were associated with the intention to get vaccinated, with security concerns preventing vaccine access being negatively associated. Among CMs, getting the Ebola vaccine was associated with the intention to get vaccinated (RR 1.43, 95% CI 1.05-1.94). Among HCWs, concerns about new vaccines' safety and side effects (OR 0.72, 95% CI 0.57-0.91), religion's influence on health decisions (OR 0.45, 95% CI 0.34-0.61), security concerns (OR 0.52, 95% CI 0.37-0.74), and governmental distrust (OR 0.50, 95% CI 0.35-0.70) were negatively associated with vaccine perceptions. Enhanced community engagement and communication that address this population's concerns could help improve vaccine perceptions and vaccination decisions. These findings could facilitate the success of vaccine campaigns in North Kivu and similar settings.

2.
Physician Leadership Journal ; 10(2):68-71, 2023.
Article in English | ProQuest Central | ID: covidwho-2249048

ABSTRACT

During the COVID-19 pandemic, we supported vaccination efforts across 17 countries through logistic and technical support, through managing or supporting vaccine campaigns and the vaccination process, and through water, sanitation and hygiene (WASH) programs and biomedical waste management. In the past, the lack of equitable access to vaccines has been a problem in humanitarian and resource-poor settings;however, with such a high global demand for COVID-19 vaccines, delay in access could lead to a vicious cycle of hesitancy, low uptake and emergence of new strains.2 UNDERSTANDING VACCINE HESITANCY Vaccine hesitancy is defined as "a delay in acceptance or refusal of vaccines despite the availability of vaccination services"3 The WHO has recognized it as one of the biggest threats to global health.4 Vaccine hesitancy is contextdependent and can change over time. The first consensus definition of vaccine hesitancy was reached in 2014, when the WHO's SAGE working group on vaccine hesitancy defined it.3 Since then, there has been progress in understanding the drivers of vaccine hesitancy and in addressing them, but operational guidance on mitigating hesitancy at the community level was limited when we started working on COVID-19 vaccination. A LOCALLY RESPONSIVE FRAMEWORK FOR A GLOBAL PROBLEM Keeping in mind the urgency of the issue, the contextual differences inherent to vaccine hesitancy, and the lack of global guidance on the topic, International Medical Corps decided to create a process by which we would have some guiding values and a flexible operational process that adjusts to local conditions.

3.
Vaccines (Basel) ; 10(9)2022 Sep 15.
Article in English | MEDLINE | ID: covidwho-2044010

ABSTRACT

Vaccine hesitancy among displaced populations is associated with inequitable access to services and mistrust of authorities, among other factors. This study evaluated variations in attitudes toward COVID-19 vaccines and factors associated with vaccine acceptance among refugees and Lebanese nationals accessing 60 International Medical Corps-supported health facilities through two cross-sectional surveys pre- (n = 3927; Survey 1) and post- (n = 4174; Survey 2) vaccine rollout. Logistic regression was used to assess predictors of vaccine acceptance using the health beliefs model. Refugees comprised 52.9% (Survey 1) and 54.2% (Survey 2) of respondents. Vaccine acceptance was low among both groups in Survey 1 (25.9% refugees vs. 23.1% Lebanese nationals), but higher in Survey 2 in Lebanese (57.6%) versus refugees (32.9%). Participants reported greater perceived benefits of vaccination, higher perceived COVID-19 susceptibility, and lower perceived vaccination barriers in Survey 2 versus Survey 1. Post-vaccine rollout, refugees had lower odds of vaccine acceptance compared to Lebanese (OR 0.50, 95%CI 0.41-0.60), while older age (OR 1.37, 95%CI 1.06-1.78, ≥51 years vs. 18-30 years) was associated with greater vaccine acceptance. Health beliefs model variables were associated with vaccine acceptance in both surveys. Tailored strategies to respond dynamically to changes in vaccine attitudes among vulnerable groups in Lebanon are essential for equitable vaccine uptake.

4.
Emerg Infect Dis ; 28(6): 1180-1188, 2022 06.
Article in English | MEDLINE | ID: covidwho-1933530

ABSTRACT

We conducted a retrospective cohort study to assess the effect vaccination with the live-attenuated recombinant vesicular stomatitis virus-Zaire Ebola virus vaccine had on deaths among patients who had laboratory-confirmed Ebola virus disease (EVD). We included EVD-positive patients coming to an Ebola Treatment Center in eastern Democratic Republic of the Congo during 2018-2020. Overall, 25% of patients vaccinated before symptom onset died compared with 63% of unvaccinated patients. Vaccinated patients reported fewer EVD-associated symptoms, had reduced time to clearance of viral load, and had reduced length of stay at the Ebola Treatment Center. After controlling for confounders, vaccination was strongly associated with decreased deaths. Reduction in deaths was not affected by timing of vaccination before or after EVD exposure. These findings support use of preexposure and postexposure recombinant vesicular stomatitis virus-Zaire Ebola virus vaccine as an intervention associated with improved death rates, illness, and recovery time among patients with EVD.


Subject(s)
Ebola Vaccines , Ebolavirus , Hemorrhagic Fever, Ebola , Vesicular Stomatitis , Animals , Democratic Republic of the Congo/epidemiology , Ebolavirus/genetics , Hemorrhagic Fever, Ebola/diagnosis , Hemorrhagic Fever, Ebola/epidemiology , Hemorrhagic Fever, Ebola/prevention & control , Humans , Retrospective Studies , Vaccination , Vaccines, Attenuated , Vesicular Stomatitis/chemically induced , Vesiculovirus/genetics
SELECTION OF CITATIONS
SEARCH DETAIL